Health Economics. The Basics. Pat Berrigan Fall 2015

Similar documents
What is costeffectiveness?

Cost-Benefit and Cost-Effectiveness Analysis. Kevin Frick, PhD Johns Hopkins University

ACTIVELY MANAGED DRUG SOLUTIONS. for maintenance and specialty medication. Actively Managed Drug Solutions is not available in the province of Quebec

Health Economics South West Webinar Series 12 October 2015 Rebecca Worboys presenting Nicola Bowtell Facilitating Dominic Gallagher Facilitating

Marina Richardson, M.Sc. Deb Willems, BSc.PT David Ure, OT Robert Teasell, MD FRCPC

SENSITIVITY ANALYSIS AND INFERENCE. Lecture 12

ENGINEERING ECONOMICS AND FINANCE

What is a QALY? What is...? series. Second edition. Health economics. Supported by sanofi-aventis

Review 3. Table The following table presents cost and revenue information for Soper s Port Vineyard.

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Are insulin analogs worth their cost in type 2 diabetes?

Charts, Tables, and Graphs

Measuring GDP and Economic Growth

Let s talk about Critical Illness insurance

Service delivery interventions

Clinical research trials and insurance

CRITICAL ILLNESS INSURANCE. ExtensiA. The ideal complement to your group insurance

Prospect Theory Ayelet Gneezy & Nicholas Epley

Chapter 5. Random variables

Summary 1. Comparative-effectiveness

Types of Studies. Systematic Reviews and Meta-Analyses

Hindrik Vondeling Department of Health Economics University of Southern Denmark Odense, Denmark

CALCULATIONS & STATISTICS

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental

MEASURING A NATION S INCOME

ALBERTA S HEALTH SYSTEM PERFORMANCE MEASURES

PUBLIC HEALTH OPTOMETRY ECONOMICS. Kevin D. Frick, PhD

Tools for Project Evaluation. Nathaniel Osgood 1.040/1.401J 2/11/2004

Cost Effectiveness, Reimbursement and Medical Devices. Colin Hopley M.Eng MBA MPH

Advance Care Planning

SHORT-TERM DECISION MAKING DIFFERENTIAL (INCREMENTAL) ANALYSIS

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Booklet A3: Cost-effectiveness Analysis

Cost-Effectiveness Analysis (CEA)

A Sales Strategy to Increase Function Bookings

2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.

Econ 201 Exam 1 F2002 Professor Phil Miller Name: Student Number:

A GUIDE TO ADVANCE CARE PLANNING

Chapter 3 Office of Human Resources Absenteeism Management

Quantitative vs. Categorical Data: A Difference Worth Knowing Stephen Few April 2005

HOMEOPATHY AS AN ALTERNATIVE TO ANTIBIOTICS

TRADE AND INVESTMENT IN THE NATIONAL ACCOUNTS This text accompanies the material covered in class.

Planning care for critically ill patients in the Intensive Care Unit

PROJECT CRITERIA: ECONOMIC VIABILITY AND PROJECT ALTERNATIVES

Market Failure. presented by: Dr. Ellen Sewell

Endpoints and quality of life

Family Caregiver s Guide to Hospice and Palliative Care

1. Comparative effectiveness of alemtuzumab

Statistical handling of data in economic analysis

Section 6.1 Discrete Random variables Probability Distribution

Midterm exam, Health economics, Spring 2007 Answer key

Chapter 1 Introduction to Correlation

Chapter 4. Probability and Probability Distributions

Chapter 10. Key Ideas Correlation, Correlation Coefficient (r),

Fixed-Effect Versus Random-Effects Models

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial

Critical Appraisal of Article on Therapy

Cancer Drug Reimbursement within the Context of Clinical Trials. (Draft for consultation purposes) Version 8.0

Nominal, Real and PPP GDP

Consumers face constraints on their choices because they have limited incomes.

Tinnitus: a brief overview

Management Accounting 303 Segmental Profitability Analysis and Evaluation

EQUATIONS and INEQUALITIES

Companies already have customer data Creating a more effective sales team With all of this improved technology Most companies have a CRM

How to Choose the Best Bank for Your Medical Practice

Domestic and International Medical Device Reimbursement

Mediation, Judicial Settlement Conferences and Negotiation Skills

Congratulations! Handling Job Offers

Measuring the Cost of Living THE CONSUMER PRICE INDEX

Section 2 - Key Account Management - Core Skills - Critical Success Factors in the Transition to KAM

SINGLE PREMIUM LIFE. PRODUCER GUIDE For Agent use only. The Solution Before life presents the problem. SPL190

What are health utilities?

"Statistical methods are objective methods by which group trends are abstracted from observations on many separate individuals." 1

Application of linear programming methods to determine the best location of concrete dispatch plants

Review Solutions FV = 4000*(1+.08/4) 5 = $

Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Robert and Mary Sample

APPENDIX. Interest Concepts of Future and Present Value. Concept of Interest TIME VALUE OF MONEY BASIC INTEREST CONCEPTS

The Envision process Defining tomorrow, today

University of Miami Department of Management School of Business Administration. MGT 684, Section 66 Analysis of Health Care Delivery and Policy

Biotechnical Engineering PLTW Scope and Sequence Year at a Glance First Semester

U.S. Food and Drug Administration

Investing Practice Questions

Understanding Clinical Trials

HIRING A QUALIFIED OFFICE STAFF

Commissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12

Transcription:

Health Economics The Basics Pat Berrigan Fall 2015 1

Topics 1) What is heath economics and why do we do it; 2) Types of health economic analyses; 3) Cost-effectiveness analysis; 4) The incremental cost-effectiveness ratio (ICER); 5) The quality adjusted life year (QALY); 6) Cost utility analysis; 7) The importance of choosing the right comparator; 8) Sourcing the data; 9) Additional resources. 2

What is Health Economics? Health economics is the study of the allocation of scarce healthcare resources. Health economists weigh the costs and benefits of healthcare interventions to help decision makers determine which to provide and which are too expensive for the public healthcare system. 3

Why do Health Economics? As a society we have an infinite number of places to spend resources but a finite budget. As a result choice is necessary. Health economics helps us make choices such that we allocate our resources in a reasonably Efficient manor. Health economics is less about saving money and more about spending money wisely. To ensure healthcare resources are allocated in an efficient manor, health economists rely on various types of economic analyses. 4

Types of Economic Analysis Types of Economic Analysis Method Input(s) Interpretation 1. Cost minimization analysis - Costs: measured in ($). Identifying the least costly option, when all interventions are equally effective. 2. Cost benefit analysis - Costs: measured in ($). - Benefits: measured in ($). 3A. Cost-effectiveness analysis 3B. Cost utility analysis (A specific type of costeffectiveness analysis) - Costs: measured in ($). - Benefits: measured in natural units (ex. lives saved). - Costs: measured in ($). - Benefits: measured using QoL. Convert all costs and benefits into $. An intervention should be adopted if the sum of all benefits exceeds the sum of all costs. How much more does it cost to gain an additional unit of benefit. How much more does it cost to gain an additional unit of benefit measured in HRQoL. Occasionally, cost minimization analysis is used. However, healthcare interventions are not often equally as effective. Rarely, cost benefit analysis (CBA) is used. CBA requires assigning $ values to human health. For moral and ethical reasons many people are uncomfortable with this. The bulk of modern health economic research is conducted using cost-effectiveness analysis (specifically cost utility analysis). 5

Cost-effectiveness Analysis Cost-effectiveness/cost utility analysis in a nutshell (5 Step Process): 1) Identify the new intervention and comparator to be analyzed. 2) To determine effectiveness, select a single clinical outcome (i.e. lives saved, cases cured, Health Related Quality of Life, etc.) and determine its value for both the new intervention and the comparator. 3) Identify, determine, and aggregate all costs associated with the new intervention and the comparator (separately). Both present and future costs should be considered. 4) Divide the difference in costs by the difference in effectiveness associated with both the new intervention and the comparator. 5) Compare the outcome from step 4) to the Willingness-to-Pay for the outcome of interest. 6

Cost-effectiveness Analysis Possible Costs Possible Effectiveness - Pharmaceuticals - # of successful treatments - Additional staff - New infrastructure - Training - Patient side effects - # of life years gained - Quality of life * - Cases cured - etc. - Complications - Follow up care - Unsuccessful treatments - etc. 7

Incremental Cost-effectiveness Ratio We refer to the outcome of a cost-effectiveness analysis (the change in cost divided by the change in effectiveness) as the Incremental Cost-effectiveness Ratio (ICER). Sometimes when referring to a cost utility analysis we use the term Incremental Cost utility Ratio (ICUR) but ICER is often used interchangeably. Mathematically the ICER is given by: ICER = Cost = Cost New Cost Comparator Effectiveness Effectiveness New Effectiveness Comparator 8

Incremental Cost-effectiveness Ratio 1) What if the effectiveness is the same for each intervention? If the effectiveness is the same we do not want to do a cost-effectiveness analysis. We instead want to do a cost minimization analysis. 2) What if the ICER is negative? There are two instances when the ICER could be negative: 1) the new intervention is more costly and less effective (Comparator is superior reject new intervention); 2) the new intervention is less costly and more effective (New intervention is superior adopt new intervention). 3) What if the ICER is positive (The most common scenario)? There are two instances in which the ICER can be positive: 1) the new intervention is less costly and less effective; or 2) the new intervention is more costly and more effective. In this scenario you must compare the ICER to the willingness-to-pay for the outcome of interest. The majority of economic analysis concerns new interventions that are more effective and more costly. 9

Cost-effectiveness Analysis Example Scenario: 100 people in the Lower Case Health Authority (LCHA) suffer from XYZ Disease, a non-fatal but painful condition. Currently, LCHA physicians recommend bed rest to patients but pharmaceutical and surgical treatment options exists. LCHA decision makers have determined that they are willing to pay up to $20,000 per additional case of XYZ Disease cured. Question: Are either the pharmaceutical or surgical treatment options cost effective in this hypothetical situation? Assume treatments are mutually exclusive. cost-effectiveness example Option Description Cost per person Total cost Effectiveness (% cured) # of cases cured ICER Standard care Bed rest $0 $0 25% 25 NA Option A Option B Pharmaceutical treatment Surgical treatment $5,000 $500,000 50% 50 $20,0000 $10,000 $1,000,000 80% 80 $16,667 10

Limitations to Cost-effectiveness Analysis Limitations to cost-effectiveness analysis 1. Tough to compare across interventions, when outcomes are not the same. (Cancer vs. Heart disease) 2. Not always ideal, when outcomes are not black and white. (50% reduction in symptoms) 3. Can be difficult to account for side effects, if they do not influence costs. 4. Not all outcome measurements are easily assigned a $ value. (standard deviations) 11

Quality Adjusted Life Years (QALY) To deal with these issues health economists developed the concept of the Quality Adjusted Life Year (QALY). QALY are a measure of disease burden, including both the quality and the quantity of life of a person in a specific health state. Mathematically: QALY = (U i T i ) where i denotes time periods. 12

QALY Explained QALY = (U i T i ) QALY s have two components utility scores and time periods. Time periods are straight forward. They are just an interval of time (ex. day, week, month, year, etc.). A utility score is a measurement of health related quality of life corresponding to a single time period. To measure HRQoL for a 10 week period post Surgery X, we could obtain utility scores once a week for 10 weeks. Summing the 10 utility scores will tell us the QALY generated by this surgery. We have multiple methods for determining utility scores. 13

What are Utility Scores? 4 Methods of Calculating Utility Scores 1. Visual Analogue Scale. 2. Standard Gamble. 3. Time Trade Off. 4. Health Utility Index ( Ex. EQ-5D-5L ). 14

Calculating the QALY Disease ABC, Average HRQoL, From Onset to 5 Years 100% Perfect Health Line Health Related Quality of Life 80% 60% 40% 20% 0.9 0.8 0.7 0.6 0.5 0% Year 1 Year 2 Year 3 Year 4 Year 5 Time From Onset Make sure to convert all time periods to the same units. (days, weeks, months, years, etc.) 15

Cost Utility Analysis Example Scenario: 100 people in the Lower Case Health Authority (LCHA) suffer from XYZ Disease, a non-fatal but painful condition. Currently, LCHA physicians recommend bed rest to patients but surgical and pharmaceutical treatment options exist. LCHA decision makers have determined that they are willing to pay up to $1,500 per Quality Adjusted Life Year. Questions: Are either the pharmaceutical or surgical treatment options cost effective in this hypothetical situation? Assume treatments are mutually exclusive and life expectancy is 30 additional years. cost-effectiveness example Option Description Cost per person Total cost Avg. utility score per year QALY ICER Standard care Bed rest $0 $0 0.40 1,200 QALY NA Option A Option B Pharmaceutical treatment Surgical treatment $5,000 $500,000 0.50 1,500 QALY $1,667 $10,000 $1,000,000 0.80 2,400 QALY $833 16

Cost-effectiveness Plane More costly Reject New Intervention Less effective More effective Adopt New Intervention Origin represents standard care Less costly 17

Cost-effectiveness Plane More costly B Reject New Intervention A Less effective More effective Willingness to pay for health Adopt New Intervention Less costly 18

Choosing the Right Comparator? 19

Choosing the Right Comparator Intervention Description Cost Excavator Requires fuel, an operator, and rental fees. No personal time required but will take an operator 5 minutes. Cumbersomely large clears 75% of snow. Shovel Requires one hour of time and must purchase shovel. Clears 95% of snow. $2,000 $50 Spoon I already have a spoon but this will required 25 hours of time. The spoons small size allows me to get into every nook and cranny and remove 99.9% of snow. $600 The shovel is both more effective and less costly than the excavator. Therefore we can immediately reject the excavator. The decision boils down to whether the additional 4.9% of effectiveness is worth the additional $550. However if we did not include the shovel as a comparator we would have concluded that the most effective method for shoveling snow is the spoon. Having chosen the wrong comparator is usually not as obvious in healthcare but the implications can be severe. 20

Where Does the Data Come From? Inputs/Outputs Data Inputs/Outputs Where to find? 1. Cost ($) Cost data can be obtained through external databases (CIHI or Health Data Nova Scotia), Bottom up costing (labor intensive), Costs can also be estimated via survey (case dependant) or from literature. 2. Benefits (Natural units) Natural units usually come from clinical trials and/or literature. 3. Benefits (Quality Adjusted Life years (QALY)) Utility scores can be taken from literature or surveyed directly. 4. Incremental cost-effectiveness Ratio (ICER) This is generally the objective of economic analysis and are calculated oneself. They can also be taken from literature. 21

Additional Resources Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Drummond, Michael F., Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, and Greg L. Stoddart. "Methods for the economic evaluation of health care programmes." OUP Catalogue (2005). 22

Acknowledgements 23